微信扫一扫
实时资讯全掌握
|
Genentron is a small biotechnology firm that is developing new therapies and drugs for different types of cancer. Genentron has a number of benefits for its employees, including a defined benefit pension plan. The plan is overseen by Rolf Pyle and Shannon DeGroot, both senior executives with Genentron. Most of Genentron’s employees are younger, so Pyle and DeGroot have invested the pension plan’s investment portfolio aggressively. Currently, the pension portfolio allocation is 30% in the Russell 1000 Growth Index and 70% in the Commodore Health Care Fund. Pyle and DeGroot are discussing the allocation of the plan at the most recent meeting. Pyle states, “If the health care industry leads the market again this year, it is unlikely that our pension expense will have much impact on our strong earnings, and we will be able to share more of those earnings with our shareholders.” DeGroot replies, “The allocation of our pension assets should ensure that Genentron will not have to make large pension contributions even if profitability is low.” With regard to their statements about Genetron’s pension plan: A. Pyle’s statement is correct; DeGroot’s statement is correct. B. Pyle’s statement is incorrect; DeGroot’s statement is incorrect. C. Pyle’s statement is correct; DeGroot’s statement is incorrect. |